December 5th 2023
Frontline treatment with enfortumab vedotin/pembrolizumab is associated with the highest healthcare costs for patients with locally advanced or metastatic urothelial carcinoma.
Oncology Financial Navigator Interventions Provide Benefits to Patients With Hematologic Cancers
March 30th 2023To evaluate the prevalence of financial toxicity and observe the effect of Coverage and Cost-of-Care Links, a program providing financial navigation, investigators initiated a nonrandomized study.
Defining and Quantifying the Oncology Nurse Navigator Role
October 7th 2021Deidra Hamilton, MSN, RN, OCN, ONN-CG, recently presented on how cancer institutions can clearly define the role of a nurse navigator to prevent scope creep and use gap analysis and metrics to showcase the value of a navigator in their program.